Table 1.
Characteristics of study participants
| All (n = 142) | Death (n = 29) | Alive (n = 113) | P value | |
|---|---|---|---|---|
| Age (years) | 58 ± 14 | 60 ± 11 | 58 ± 15 | 0.290 |
| Male gender | 83 (58.5) | 19 (65.5) | 64 (56.6) | 0.513 |
| Systolic BP (mmHg) | 123 ± 33 | 112 ± 31 | 125 ± 33 | 0.034 |
| Diastolic BP (mmHg) | 79 ± 21 | 73 ± 22 | 80 ± 20 | 0.095 |
| Heart rate (bpm) | 95 ± 22 | 101 ± 24 | 93 ± 21 | 0.103 |
| LVEF | 31.8 ± 11.0 | 28.7 ± 9.5 | 32.6 ± 11.4 | 0.139 |
| Hypertension | 84 (59.2) | 17 (58.6) | 67 (59.3) | 0.884 |
| Diabetes | 23 (16.2) | 4 (13.8) | 19 (16.8) | 0.911 |
| Dyslipidaemia | 11 (7.7) | 1 (3.4) | 10 (8.8) | 0.561 |
| CKD | 26 (18.3) | 4 (13.8) | 22 (19.5) | 0.663 |
| Smoking | 20 (14.1) | 5 (17.2) | 15 (13.3) | 0.804 |
| Myocardial necrosis | 32 (22.5) | 4 (13.8) | 28 (24.8) | 0.311 |
| Atrial fibrillation | 36 (25.4) | 11 (37.9) | 25 (22.1) | 0.132 |
| Complete LBBB | ||||
| Liver disease | 15 (10.6) | 3 (10.3) | 12 (10.6) | 0.767 |
| Cancer | 8 (5.6) | 1 (3.4) | 7 (6.2) | 0.904 |
| Hypertensive heart disease | 57 (40.1) | 14 (48.3) | 43 (38.1) | 0.430 |
| Hypertrophic cardiomyopathy | 48 (33.8) | 11 (37.9) | 37 (32.7) | 0.759 |
| Ischemic cardiomyopathy | 31 (21.8) | 3 (10.3) | 28 (24.8) | 0.154 |
| Valvular heart disease | 4 (2.8) | 1 (3.4) | 3 (2.7) | 0.690 |
| Anaemia | 69 (48.6) | 13 (44.8) | 56 (49.6) | 0.805 |
| Prothrombin time <50% | 14 (9.9) | 6 (20.7) | 8 (7.1) | 0.036 |
| Hyponatraemia | 38 (26.5) | 10 (35.0) | 28 (24.4) | 0.335 |
| Use of dobutamine | 23 (16.2) | 9 (31.0) | 14 (12.4) | 0.032 |
| Use of ACEI/ARAII | 137 (96.5) | 26 (89.7) | 111 (98.2) | 0.025 |
| Creatininemia (mg/dL) | 27.7 ± 39.8 | 51.8 ± 74.3 | 20.4 ± 16.3 | 0.015 |
ACCEI, angiotensin‐converting enzyme inhibitor; ARA‐II, Angiotensin II receptor antagonists; BP, blood pressure; CKD, chronic kidney disease; LVEF, left ventricular ejection fraction.